{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:19:38Z","timestamp":1790633978821,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aim of the study was to assess the role of magnetic resonance enterography (MRE) in predicting one-year efficacy of anti-tumor necrosis factor antibodies - infliximab (IFX), adalimumab (ADA) in Crohn\u2019s disease (CD) patients primarily responding to therapy. We performed retrospective analysis among 61 CD patients who had undergone a successful IFX\/ADA induction therapy and were treated with maintenance doses. All patients underwent MRE at week 0. We assessed which MRE features were predictive for steroid-free remission at week 52 and which were associated with a secondary loss of response. 44 patients were in steroid-free remission at week 52, 17 - were secondary non-responders. The ROC curve showed that bowel thickening with contrast enhancement analyzed together at week 0 were associated with steroid-free remission at week 52 (p\u2009=\u20090.01; AUC 0.67). Bowel stenosis with or without prestenotic dilatation [OR 5.8 (95% CI 1.4\u2009\u2013\u200925) and 2.4 (95% CI 1.2\u2009\u2013\u20095) respectively; p\u2009=\u20090.01] and the presence of intra-abdominal fistulas [OR 1.4 (95% CI 1.1\u2009\u2013\u20092); p\u2009=\u20090.004] were related to secondary non-response. A high baseline inflammatory activity detected by MRE predicts one-year response in CD after IFX\/ADA. In case of bowel stenosis, intra-abdominal fistulas, other therapeutic options should be considered.<\/jats:p>","DOI":"10.1038\/srep10223","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T11:29:32Z","timestamp":1432121372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn\u2019s disease treated with anti-tumor necrosis factor antibodies"],"prefix":"10.1038","volume":"5","author":[{"given":"Piotr","family":"Eder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Katulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Lykowska-Szuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Krela-Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Stawczyk-Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Klimczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Linke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"BFsrep10223_CR1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ibd.21870","volume":"1","author":"BG Feagan","year":"2012","unstructured":"Feagan, B. G. et al. Recommendations for the treatment of Crohn\u2019s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm. Bowel Dis. 1, 152\u2013160 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","volume":"4","author":"M Allez","year":"2010","unstructured":"Allez, M. et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns Colitis 4, 355\u2013366 (2010).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/flgastro-2012-100241","volume":"4","author":"S Vermeire","year":"2013","unstructured":"Vermeire, S. & Gils, A. Value of drug level testing and antibody assays in optimizing biological therapy. Frontline Gastroenterology 4, 41\u201343 (2013).","journal-title":"Frontline Gastroenterology"},{"key":"BFsrep10223_CR4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1756283X09336364","volume":"2","author":"CA Siegel","year":"2009","unstructured":"Siegel, C. A. & Melmed, G. Y. Predicting response to anti-TNF agents for the treatment of Crohn\u2019s disease. Ther. Adv. Gastroenterol. 2, 245\u2013251 (2009).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"BFsrep10223_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2012.10.005","volume":"8","author":"M Amitai","year":"2013","unstructured":"Amitai, M., Ben-Horin, S., Eliakim, R. & Kopylow, U. Magnetic resonance enterography in Crohn\u2019s disease: a guide to common imaging manifestations for the IBD physician. J. Crohns Colitis 8, 603\u2013615 (2013).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/MIB.0b013e31828029dd","volume":"5","author":"G Schill","year":"2013","unstructured":"Schill, G. et al. Assessment of disease behavior in patients with Crohn\u2019s disease by MR enterography. Inflamm. Bowel Dis. 5, 983\u2013990 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2214\/AJR.12.10406","volume":"1","author":"JC Makanyanga","year":"2013","unstructured":"Makanyanga, J. C. & Taylor, S. A. Current and future role of MR enterography in the management of Crohn\u2019s disease. AJR Am. J. Roentgenol. 1, 56\u201364 (2013).","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFsrep10223_CR8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ibd.21551","volume":"8","author":"J Rimola","year":"2011","unstructured":"Rimola, J. et al. Magnetic resonance imaging for evaluation of Crohn\u2019s disease: validation of parameters of severity and quantitative index of activity. Inflamm. Bowel Dis. 8, 1759\u20131768 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00261-011-9820-z","volume":"6","author":"J Rimola","year":"2012","unstructured":"Rimola, J., Ordas, I., Rodriguez, S., Ricart, E., Panes, J. Imaging indexes of activity and severity for Crohn\u2019s disease: current status and future trends. Abdom. Imaging 6, 958\u2013966 (2012).","journal-title":"Abdom. Imaging"},{"key":"BFsrep10223_CR10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.20452\/pamw.1825","volume":"7-8","author":"P Eder","year":"2013","unstructured":"Eder, P. et al. Simple Enterographic Activity Score for Crohn\u2019s Disease: comparison with endoscopic, biochemical and clinical findings. Pol. Arch. Med. Wewn. 7-8, 378\u2013385 (2013).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"BFsrep10223_CR11","first-page":"1943","volume":"19","author":"JA Tielbeek","year":"2013","unstructured":"Tielbeek, J. A. et al. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn\u2019s disease. Inflamm. Bowel Dis. 19, 1943\u20131950 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.crohns.2013.01.011","volume":"12","author":"G Van Assche","year":"2013","unstructured":"Van Assche, G. et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn\u2019s disease. J. Crohns Colitis 12, 950\u2013957 (2013).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2013.10.055","volume":"146","author":"I Ordas","year":"2014","unstructured":"Ordas, I. et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn\u2019s disease. Gastroenterology 146, 374\u2013382 (2014).","journal-title":"Gastroenterology"},{"key":"BFsrep10223_CR14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 132, 62\u201365 (2007).","journal-title":"Gastroenterology"},{"key":"BFsrep10223_CR15","first-page":"1","volume":"6","author":"J Dretzke","year":"2011","unstructured":"Dretzke, J. et al. A systematic review and economic evaluation of the use of tumour necrosis factor alpha (TNF-\u03b1) inhibitors, adalimumab and infliximab, for Crohn\u2019s disease. Health Technol. Assess 6, 1\u2013244 (2011).","journal-title":"Health Technol. Assess"},{"key":"BFsrep10223_CR16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","volume":"5","author":"W Reinisch","year":"2012","unstructured":"Reinisch, W., Wang, Y., Oddens, B. J. & Link, R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn\u2019s disease: a post-hoc analysis from ACCENT I. Aliment. Pharmacol. Ther. 5, 568\u2013576 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep10223_CR17","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ibd.22925","volume":"12","author":"DT Rubin","year":"2012","unstructured":"Rubin, D. T., Uluscu, O. & Sederman, R. Response to biologic therapy in Crohn\u2019s disease is improved with early treatment: an analysis of health claims data. Inflamm. Bowel Dis. 12, 2225\u20132231 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR18","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","volume":"17","author":"ID Arnott","year":"2003","unstructured":"Arnott, I. D., McNeill, G. & Satsangi, J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn\u2019s disease. Aliment. Pharmacol. Ther. 17, 1451\u20131457 (2003).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep10223_CR19","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","volume":"97","author":"N Esters","year":"2002","unstructured":"Esters, N. et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease. Am. J. Gastroenterol. 97, 1458\u20131462 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"BFsrep10223_CR20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/pgs.11.114","volume":"11","author":"R Prajapati","year":"2011","unstructured":"Prajapati, R., Plant, D. & Barton, A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 11, 1571\u20131585 (2011).","journal-title":"Pharmacogenomics"},{"key":"BFsrep10223_CR21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ibd.21034","volume":"15","author":"GR D\u2019Haens","year":"2009","unstructured":"D\u2019Haens, G. R. et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn\u2019s disease. Inflamm. Bowel Dis. 15, 1599\u20131604 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFsrep10223_CR22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.crohns.2013.02.020","volume":"7","author":"J Panes","year":"2013","unstructured":"Panes, J. et al. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. J. Crohns Colitis 7, 556\u2013585 (2013).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR23","first-page":"1423","volume":"32","author":"E Amzallag-Bellenger","year":"2012","unstructured":"Amzallag-Bellenger, E. et al. Effectiveness of MR enterography for the assessment of small bowel diseases beyond Crohn disease. Radio Graphics 32, 1423\u20131444 (2012).","journal-title":"Radio Graphics"},{"key":"BFsrep10223_CR24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.acra.2008.11.009","volume":"16","author":"A Oto","year":"2009","unstructured":"Oto, A. et al. Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn\u2019s disease. Acad. Radiol. 16, 597\u2013603 (2009).","journal-title":"Acad. Radiol."},{"key":"BFsrep10223_CR25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","volume":"37","author":"E Louis","year":"2002","unstructured":"Louis, E. et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818\u2013824 (2002).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFsrep10223_CR26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","volume":"5","author":"M Jurgens","year":"2011","unstructured":"Jurgens, M. et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 5, 421\u2013427 (2011).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFsrep10223_CR27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","volume":"6","author":"FS Velayos","year":"2013","unstructured":"Velayos, F. S., Kahn, J. G., Sandborn, W. J. & Feagan, B. G. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab. Clin. Gastroenterol. Hepatol. 6, 654\u2013666 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFsrep10223_CR28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","volume":"10","author":"I Ordas","year":"2012","unstructured":"Ordas, I., Feagan, B. G. & Sandborn, W. J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10, 1079\u20131087 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFsrep10223_CR29","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","volume":"7","author":"F Rieder","year":"2013","unstructured":"Rieder, F., Zimmermann, E. M., Remzi, F. H. & Sandborn, W. J. Crohn\u2019s disease complicated by strictures: a systematic review. Gut. 7, 1072\u20131084 (2013).","journal-title":"Gut."},{"key":"BFsrep10223_CR30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000117306","volume":"1","author":"D Sorrentino","year":"2008","unstructured":"Sorrentino, D. Role of biologics and other therapies in stricturing Crohn\u2019s disease: what have we learnt so far? Digestion 1, 38\u201347 (2008).","journal-title":"Digestion"},{"key":"BFsrep10223_CR31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000353373","volume":"2","author":"GM Sampietro","year":"2013","unstructured":"Sampietro, G. M., Casiraghi, S. & Foschi, D. Perforating Crohn\u2019s disease: conservative and surgical treatment. Dig. Dis. 2, 218\u2013221 (2013).","journal-title":"Dig. Dis."},{"key":"BFsrep10223_CR32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04827.x","volume":"8","author":"LS Kiss","year":"2011","unstructured":"Kiss, L. S. et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 8, 911\u2013922 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFsrep10223_CR33","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","volume":"11","author":"M Henriksen","year":"2008","unstructured":"Henriksen, M. et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 11, 1518\u20131523 (2008).","journal-title":"Gut."},{"key":"BFsrep10223_CR34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","volume":"8","author":"F Magro","year":"2014","unstructured":"Magro, F. et al. High C-reactive protein in Crohn\u2019s disease patients predicts nonresponse to infliximab treatment. J. Crohns Colitis 8, 129\u2013136 (2014).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3748\/wjg.v17.i5.578","volume":"5","author":"WE Cromer","year":"2011","unstructured":"Cromer, W. E., Mathis, J. M., Granger, D. N., Chaitanya, G. V. & Alexander, J. S. Role of the endothelium in inflammatory bowel diseases. World J. Gastroenterol. 5, 578\u2013593 (2011).","journal-title":"World J. Gastroenterol."},{"key":"BFsrep10223_CR36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","volume":"9","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn, W. J. et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J. Crohns Colitis 9, 927\u2013935 (2014).","journal-title":"J. Crohns Colitis"},{"key":"BFsrep10223_CR37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2214\/ajr.177.6.1771325","volume":"177","author":"DM Koh","year":"2001","unstructured":"Koh, D. M. et al. MR imaging evaluation of the activity of Crohn\u2019s disease. Am. J. Roentgenol. 177, 1325\u20131332 (2001).","journal-title":"Am. J. Roentgenol."},{"key":"BFsrep10223_CR38","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s00330-008-1287-0","volume":"19","author":"K Horthuis","year":"2009","unstructured":"Horthuis, K., Bipat, S., Stokkers, P. C. & Stoker, J. Magnetic resonance imaging for evaluation of disease activity in Crohn\u2019s disease: a systematic review. Eur. Radiol. 19, 1450\u20131460 (2009).","journal-title":"Eur. Radiol."},{"key":"BFsrep10223_CR39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.rx.2010.10.002","volume":"53","author":"JC Gallego Ojea","year":"2011","unstructured":"Gallego Ojea, J. C., Echarri Piudo, A. I & Porta Vila, A. Crohn\u2019s disease: the usefulness of MR enterography in the detection of recurrence after surgery. Radiologia. 53, 552\u2013559 (2011).","journal-title":"Radiologia"},{"key":"BFsrep10223_CR40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1148\/rg.302095028","volume":"30","author":"DJ Tolan","year":"2010","unstructured":"Tolan, D. J. et al. MR enterographic manifestations of small bowel Crohn\u2019s disease. RadioGraphics 30, 367\u2013384 (2010).","journal-title":"RadioGraphics"},{"key":"BFsrep10223_CR41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1148\/radiol.2523082167","volume":"252","author":"S Punwani","year":"2009","unstructured":"Punwani, S. et al. Mural inflammation in Crohn\u2019s disease: location-matched histologic validation of MR imaging features. Radiology 252, 712\u2013720 (2009).","journal-title":"Radiology"},{"key":"BFsrep10223_CR42","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1055\/s-0033-1335445","volume":"184","author":"S Schleder","year":"2013","unstructured":"Schleder, S. et al. Interobserver agreement in MR enterography for diagnostic assessment in patients with Crohn\u2019s disease. Rofo. 184, 992\u2013997 (2013).","journal-title":"Rofo."},{"key":"BFsrep10223_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/flgastro-2011-100007","volume":"3","author":"H Bungay","year":"2012","unstructured":"Bungay, H. Small bowel imaging in Crohn\u2019s disease. Frontline Gastroenterol. 3, 39\u201346 (2012).","journal-title":"Frontline Gastroenterol."},{"key":"BFsrep10223_CR44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best, W. R., Becktel, J. M., Singelton, J. W. & Kern, F. Jr. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology 70, 439\u2013444 (1976).","journal-title":"Gastroenterology"},{"key":"BFsrep10223_CR45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest. Endosc. 60, 505\u201312 (2004).","journal-title":"Gastrointest. Endosc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10223","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T21:32:21Z","timestamp":1748381541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep10223"],"URL":"https:\/\/doi.org\/10.1038\/srep10223","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]},"assertion":[{"value":"4 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PE, LLS and KK received lecture fees from Abbvie Poland. Other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10223"}}